MicroRNA gene dosage alterations and drug response in lung cancer
- PMID: 21541180
- PMCID: PMC3085440
- DOI: 10.1155/2011/474632
MicroRNA gene dosage alterations and drug response in lung cancer
Abstract
Chemotherapy resistance is a key contributor to the dismal prognoses for lung cancer patients. While the majority of studies have focused on sequence mutations and expression changes in protein-coding genes, recent reports have suggested that microRNA (miRNA) expression changes also play an influential role in chemotherapy response. However, the role of genetic alterations at miRNA loci in the context of chemotherapy response has yet to be investigated. In this study, we demonstrate the application of an integrative, multidimensional approach in order to identify miRNAs that are associated with chemotherapeutic resistance and sensitivity utilizing publicly available drug response, miRNA loci copy number, miRNA expression, and mRNA expression data from independent resources. By instigating a logical stepwise strategy, we have identified specific miRNAs that are associated with resistance to several chemotherapeutic agents and provide a proof of principle demonstration of how these various databases may be exploited to derive relevant pharmacogenomic results.
Figures






Similar articles
-
Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer.Genes Chromosomes Cancer. 2011 Aug;50(8):585-97. doi: 10.1002/gcc.20880. Epub 2011 May 11. Genes Chromosomes Cancer. 2011. PMID: 21563230
-
The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.J Exp Clin Cancer Res. 2015 Oct 14;34:121. doi: 10.1186/s13046-015-0235-5. J Exp Clin Cancer Res. 2015. PMID: 26467212 Free PMC article.
-
MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma.PLoS One. 2010 Sep 3;5(9):e12560. doi: 10.1371/journal.pone.0012560. PLoS One. 2010. PMID: 20838434 Free PMC article.
-
The emerging role of microRNAs in resistance to lung cancer treatments.Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25592062 Review.
-
microRNA regulation of cell viability and drug sensitivity in lung cancer.Expert Opin Biol Ther. 2012 Sep;12(9):1221-39. doi: 10.1517/14712598.2012.697149. Epub 2012 Jun 26. Expert Opin Biol Ther. 2012. PMID: 22731874 Review.
Cited by
-
Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.Int J Mol Med. 2013 Sep;32(3):557-67. doi: 10.3892/ijmm.2013.1424. Epub 2013 Jun 21. Int J Mol Med. 2013. PMID: 23799609 Free PMC article.
-
Small non-coding RNA transcriptome of the NCI-60 cell line panel.Sci Data. 2017 Oct 24;4:170157. doi: 10.1038/sdata.2017.157. Sci Data. 2017. PMID: 29064465 Free PMC article.
-
Non-coding RNAs in lung cancer.Oncoscience. 2014 Nov 15;1(11):674-705. doi: 10.18632/oncoscience.98. eCollection 2014. Oncoscience. 2014. PMID: 25593996 Free PMC article. Review.
-
A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.RNA Biol. 2013 Nov;10(11):1700-13. doi: 10.4161/rna.26541. Epub 2013 Sep 30. RNA Biol. 2013. PMID: 24157646 Free PMC article.
-
Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening.mBio. 2016 Aug 2;7(4):e01073-16. doi: 10.1128/mBio.01073-16. mBio. 2016. PMID: 27486194 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: Cancer Journal for Clinicians. 2010;60(5):277–300. - PubMed
-
- Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005;10(3):1–10. - PubMed
-
- Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14(3):253–263. - PubMed
-
- Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2003;21(12):2237–2246. - PubMed
-
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine. 2009;361(10):947–957. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical